| Catalog No | Package | Original Price | Price | Inventory | Quantity | Operating |
|---|---|---|---|---|---|---|
| BP5114-5mg | 5mg | $350.00 | Sign in |
|
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Natural products, as important resources for drug discovery, hold an irreplaceable position in modern pharmacological research. Lignin derivatives have attracted increasing attention in recent years due to their unique structure and diverse biological activities. Su-style gua β iacol glycerol-β-O-4'-sinapyl ether (CAS No.: 288864-26-6) is a typical lignin model compound, belonging to the β-O-4' type bisphenol compound with potential pharmacological activity and good druggability parameters. This paper will systematically review the chemical structure and physicochemical properties of this compound, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation and pharmacokinetic characteristics, explore its clinical application prospects and development trends, and aim to provide reference and guidance for pharmacological research of natural products.
Su-style guaiazoinisol glycerol-β-O-4'-mustazisol ether has a molecular formula of C22H26O8 and a molecular weight of 406.4310. Its structural feature is that guaiac glycerol and sinapyl alcohol are connected by β-O-4' ether bonds, making it a typical lignin β-O-4' linking unit. The sterotype of this compound is threo, indicating that the spatial arrangement of its two chiral centers is trans. The structure contains multiple hydroxyl and methoxy groups, giving it high polarity and hydrogen bond donor capability.
In terms of physicochemical properties, the compound has a LogP value of 1.4730, indicating moderate lipid solubility, which facilitates cell membrane penetration. The topological pole surface area (TPSA) is 117.8400 Ų, indicating high polarity and favorable water phase solubility. Its water solubility is 1.1806, indicating a certain solubility in physiological environments. The blood-brain barrier has low penetration capacity, suggesting its limited distribution in the central nervous system. The hERG channel inhibition test was negative, indicating a lower risk of cardiotoxicity. The Ames test result was 0.0, indicating no mutagenicity and good safety.
Su-style guaiacol glycerol-β-O-4'-mustilate ether is mainly found in various lignin-rich plants, especially the xylem tissues of grasses and dicotyledonous plants. As one of the degradation products of lignin, this compound is commonly found in wood, plant fibers, and their processing by-products. Typical plant sources include poplar (Populus spp.), willow (Salix spp.), and certain grasses such as corn and wheat stems.
The extraction method mainly relies on chemical or enzymatic degradation techniques for lignin. Common extraction processes include:
In recent years, research on bioenzymatic degradation of lignin and enrichment of this compound has gradually increased, demonstrating advantages of green environmental friendliness and high selectivity.
Pharmacological activity studies of Sus-style guaiazoinidrine lignophenol-glycerol-β-O-4'-mustaziol ether mainly focus on its antioxidant, anti-inflammatory, antitumor, and neuroprotective aspects.
Antioxidant activity
This compound contains multiple phenolic hydroxyl groups and has strong free radical scavenging ability. In vitro DPPH and ABTS radical scavenging experiments have shown significant antioxidant activity, effectively inhibiting lipid peroxidation and protecting cells from oxidative stress damage.
Anti-inflammatory effects
In inflammation models, this compound reduces inflammatory responses by inhibiting the production of inflammatory mediators such as TNF-α, IL-6, and NO. Its mechanism involves inhibition of the NF-κB signaling pathway, reducing the transcriptional activity of inflammatory genes.
Anti-tumor effects
Cell-level studies have shown that Su-style guaiacinsory lignophenol-glyceryl-β-O-4'-mustaziol ether can induce tumor cell apoptosis and inhibit cell proliferation. Its effect may be achieved by regulating cyclins and activating mitochondrial apoptosis pathways.
Neuroprotective effects
Although the blood-brain barrier permeability is relatively low, in vitro models of neurons, this compound demonstrated protective effects against oxidative stress-induced nerve cell damage, suggesting its potential application value in peripheral nervous system diseases.
The pharmacological activity of Su-style guaiasolate glycerol-β-O-4'-glucositol ether is closely related to its molecular structure. Its polyphenol structure allows it to directly eliminate free radicals and reduce oxidative stress. Additionally, this compound exerts biological effects by regulating multiple signaling pathways:
NF-κB signaling pathway
This compound inhibits the phosphorylation and degradation of IκBα, blocking NF-κB transcription factors from entering the cell nucleus, thereby suppressing inflammatory factor expression and alleviating inflammatory responses.
MAPK signaling pathway
Research shows that it can regulate the activities of ERK, JNK, and p38 MAPK, affecting cell proliferation and apoptosis.
Mitochondrial apoptosis pathway
By regulating the expression of Bcl-2 family proteins, it promotes the release of cytochrome c, activates the caspase cascade, and induces tumor cell apoptosis.
Antioxidant defense mechanisms
This compound activates the Nrf2/ARE signaling pathway, promoting the expression of antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPx), thereby enhancing intracellular antioxidant capacity.
Druggability evaluation showed that Su-style guaiasosol lignylglycerin-β-O-4'-mustazithane exhibited good drug compatibility and safety. Its moderate LogP value indicates good cell membrane permeability; Higher TPSA and water solubility help with distribution and metabolism in the body. hERG channels have no inhibitory effects, reducing the risk of cardiotoxicity. Ames test was negative, indicating no risk of mutation.
Pharmacokinetic studies have shown that this compound is well absorbed orally, but due to low blood-brain barrier permeability, its distribution in the central nervous system is limited. Metabolism in the body mainly occurs through phase I and phase II enzyme systems in the liver, including hydroxylation, methylation, and glucuronic acid binding reactions. The main excretory pathways are the kidneys and bile.
Additionally, it has a moderate half-life in vivo and high bioavailability, making it suitable for oral administration. No significant risk of drug interactions, indicating its potential as a candidate drug.
Su-style guaiacon lignosterylglycerin-β-O-4'-mustaziol ether, due to its multiple pharmacological activities and good safety profile, has broad clinical application prospects. Its anti-inflammatory and antioxidant properties give it potential as an adjunct treatment for chronic inflammatory diseases, metabolic syndrome, and cardiovascular diseases. Antitumor activity suggests it can serve as a novel natural drug candidate for adjuvant therapy in tumors.
Future research should focus on:
In-depth analysis of pharmacodynamic mechanisms
By integrating modern technologies such as genomics and proteomics, the target mechanisms and signaling pathway networks are systematically clarified.
Pharmacokinetic and toxicological systematic evaluation
Conduct long-term toxicological studies to clarify safe dose ranges and potential toxicity.
Formulation development and route of administration optimization
To address the issue of insufficient blood-brain barrier permeability, new delivery systems such as nanocarriers have been developed to improve targeting and bioavailability.
Preclinical and clinical research
Conduct animal models and early clinical trials to verify efficacy and safety, and promote clinical translation.
Su-style guaiasosophilylglycerol-β-O-4'-mustazithanol ether, as a typical lignin-derived natural product, exhibits rich pharmacological activity and good druggability. Its multiple biological effects—antioxidant, anti-anti-inflammation, and anti-tumor—provide a solid foundation for the development of novel natural drugs. In the future, through in-depth mechanistic research, pharmacokinetic optimization, and clinical validation, it is expected to develop into an effective drug for treating multiple diseases. The field of natural product pharmacology should continue to focus on research on such lignin derivatives, promoting the rational use of natural product resources and the development of innovative drugs.
